Orientations

Off-label vaccine use: explanatory note for countries

World Health Organization (WHO)

The document explains what off-label use of a vaccines is, why SAGE makes off-label recommendations and describes considerations for countries when using a vaccine off-label.  

Auteurs

Langues

  • Anglais

Année de publication

2024

Type

Orientations

Catégories

Maladies

Organisations

Mpox-Policy

Cette ressource apparaît sur le Thème suivant:

Cette ressource est incluse dans le tableau suivant:

TitreAuteurAnnéeTypeLangue
ETF statement on the use of Imvanex for the prevention of mpox in children below 12 years of ageEuropean Medicines Agency2024GuidanceAnglais
Frequently Asked Questions (FAQ) on use of fractional dosing with intradermal administration of mpox MVA-BN vaccine in the context of vaccine supply-constrained outbreak responseWorld Health Organization (WHO)2025GuidanceAnglais
LC16m8 (live-attenuated freeze-dried vaccinia) smallpox and mpox vaccine - Interim GuidanceWorld Health Organization (WHO)2025GuidanceAnglais, Français
MVA-BN (‎Modified Vaccinia Ankara – Bavarian Nordic)‎ smallpox and mpox vaccine: Interim guidanceWorld Health Organization (WHO)2024GuidanceAnglais, Français
Off-label vaccine use: explanatory note for countriesWorld Health Organization (WHO)2024GuidanceAnglais
Regulatory & Policy Considerations for Mpox Vaccines in African CountriesWorld Health Organization (WHO), European Medicines Agency, Bavarian Nordic2025PresentationAnglais
Smallpox and mpox (orthopoxviruses): WHO position paperWorld Health Organization (WHO)2024GuidanceAnglais, Français
Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label useWorld Health Organization (WHO)2025PresentationAnglais

Mpox-Policy-FR

Cette ressource est incluse dans le tableau suivant:

TitreAuteurAnnéeTypeLangue
Vaccin contre la variole et la mpox MVA-BN (‎Modified Vaccinia Ankara - Bavarian Nordic)‎ : directives provisoiresWorld Health Organization (WHO)2024GuidanceFrançais, Anglais
ETF statement on the use of Imvanex for the prevention of mpox in children below 12 years of ageEuropean Medicines Agency2024GuidanceAnglais
Frequently Asked Questions (FAQ) on use of fractional dosing with intradermal administration of mpox MVA-BN vaccine in the context of vaccine supply-constrained outbreak responseWorld Health Organization (WHO)2025GuidanceAnglais
Note de synthèse: position de l’OMS sur les vaccins contre la variole et la mpox (orthopoxvirus)World Health Organization (WHO)2024GuidanceFrançais, Anglais
Off-label vaccine use: explanatory note for countriesWorld Health Organization (WHO)2024GuidanceAnglais
Regulatory & Policy Considerations for Mpox Vaccines in African CountriesWorld Health Organization (WHO), European Medicines Agency, Bavarian Nordic2025PresentationAnglais
Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label useWorld Health Organization (WHO)2025PresentationAnglais
Vaccin LC16m8 (‎vaccin lyophilisé vivant atténué)‎ contre la variole et la variole du singe : directives provisoiresWorld Health Organization (WHO)2025GuidanceFrançais, Anglais
Log in to vote

Ajouté par: Géraldine Nemrod

Ajouté le: 2024-11-19 15:07:53

Consultations: 1148

Liens

Signaler un problème

Ajouter une ressource